Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | CRHBP | P24387 | 2/20 | 0.30 |
| ▸ | CRHR2 | Q13324 | 2/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5244917 | 0.93 | — | — | |
| SCHEMBL14410331 | 0.93 | — | — | |
| SCHEMBL8055082 | 0.78 | SMN1; SMN2 (0.33) | SMN1; SMN2LMNACRHBPCRHR2HTT | |
| SCHEMBL7110673 | 0.77 | CA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL7111096 | 0.77 | CA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL7110862 | 0.77 | CA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL7106044 | 0.77 | CA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL7110857 | 0.77 | CA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL7112142 | 0.77 | CA1 (0.36) | SMN1; SMN2 | |
| SCHEMBL7106025 | 0.77 | CA1 (0.36) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513188-B2 | Formulations comprising cyclic compounds | CAPSUGEL BELGIUM (BE) | 2013-08-20 | — | — | US | disclosed |
| US-8513188-B2 | Formulations comprising cyclic compounds | CAPSUGEL BELGIUM (BE) | 2013-08-20 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | CAPSUGEL BELGIUM (BE) | 2010-06-03 | — | — | US | disclosed |
| WO-2008037484-A2 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | BOTTI PAOLO (CH) | 2008-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137188-A1 | FORMULATIONS COMPRISING CYCLIC COMPOUNDS | SLC2A1, SLC2A4, SLC2A9 | SMN1; SMN2 590/4885LMNA 867/4885CRHBP 3417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.